Prescription medicine
Triheptanoin Brand names: Dojolvi
Triheptanoin (Dojolvi) is a prescription medicine with an FDA approval on record since 2020. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the triheptanoin FDA label on DailyMed (effective June 10, 2025, Ultragenyx Pharmaceutical Inc.); the NDA 213687 record on Drugs@FDA; every triheptanoin label on DailyMed.
Highlights of the record
FDA label of June 10, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageDOJOLVI is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).
Forms and strengths
- 0.96 g/ml
Liquid.
On the market
- Earliest approval on file
- June 30, 2020 Dojolvi, Ultragenyx Pharm Inc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- November 14, 2034 Dojolvi liquid; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 528 through July 30, 2026
What is triheptanoin used for?
From the label: indications and usageDOJOLVI is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). DOJOLVI is a medium-chain triglyceride indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).
FDA pharmacologic class: Medium-chain Triglyceride.
Source: FDA drug label (DOJOLVI), Ultragenyx Pharmaceutical Inc., effective June 10, 2025 (SPL set 4cfeb8bd-143e-4dd7-bc34-b0bcda02460d), via openFDA; the full label on DailyMed
Is there a generic for triheptanoin (Dojolvi)?
No generic triheptanoin is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 2 patents for Dojolvi liquid, the last expiring on November 14, 2034. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2020 earliest approval on file
- 2034 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the triheptanoin label say about other medicines?
The triheptanoin label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Orlistat | drug interactions | Pancreatic Lipase Inhibitors Co-administration of triheptanoin with a pancreatic lipase inhibitor (e.g., orlistat) may reduce exposure to the triheptanoin metabolite, heptanoate, and reduce the clinical effect of triheptanoin [see Clinical Pharmacology (12.3) ]. |
Source: FDA drug label (DOJOLVI), Ultragenyx Pharmaceutical Inc., effective June 10, 2025 (SPL set 4cfeb8bd-143e-4dd7-bc34-b0bcda02460d), via openFDA; the full label on DailyMed
What do FAERS reports show for triheptanoin?
The FDA Adverse Event Reporting System holds 528 reports that list triheptanoin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 68 are coded as a death and 260 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Triheptanoin side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other